



Attorney's Docket No.: 11926-015001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vincent P. Stanton, Jr. Art Unit : 1656
Serial No. : 09/658,659 Examiner : Chakrabarti
Filed : September 8, 2000
Title : GENE SEQUENCE VARIANCE IN GENES RELATED TO FOLATE
METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF
DISEASE

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 16 2001

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Correspondence relating to this application is enclosed. The required fees are computed below. Please charge any further fees, or credits, to Deposit Account No. 06-1050.

Total Claims	177	-	16	=	161	\$1449
Independent	32	-	3	=	29	\$1160
TOTAL FEE DUE						\$2609

A check for \$2609 is attached.

Respectfully submitted,

Anita L. Meiklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20237538.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 10, 2001
Date of Deposit

Signature

Carrie A. Amonte

Typed or Printed Name of Person Signing Certificate



Attorney's Docket No.: 11926-015001

HSA
P/B
4/17/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vincent P. Stanton, Jr. Art Unit : 1656
Serial No. : 09/658,659 Examiner : Chakrabarti
Filed : September 8, 2000
Title : GENE SEQUENCE VARIANCE IN GENES RELATED TO FOLATE
METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF
DISEASE

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

APR 16 2001

RESPONSE

TECH CENTER 1600/2900

In response to the action mailed January 10, 2001, please amend the application as follows:

In the claims:

Please cancel claims 1-16.

Please add new claims 1-176 as follows.

~~--X.17~~ An isolated nucleic acid probe comprising at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, the probe comprising at least one of:

- (a) nucleotide 194 wherein X is G;
- (b) nucleotide 294 wherein X is T;
- (c) nucleotide 1136 wherein X is A;
- (d) nucleotide 1252 wherein X is T;
- (e) nucleotide 1334 wherein X is A;
- (f) nucleotide 1699 wherein X is C;
- (g) nucleotide 3150 wherein X is G;
- (h) nucleotide 3207 wherein X is T;
- (i) nucleotide 3209 wherein X is A;
- (j) nucleotide 5444 wherein X is C;
- (k) nucleotide 5551 wherein X is A;

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

April 10, 2001

Signature

Carrie A. Amonte

Carrie A. Amonte

Typed or Printed Name of Person Signing Certificate

11926-015001 Docket No. 09/658,659

149.00 00
1150.00 00

11926-015001
11926-015001